Purity-activity relationships of natural products: the case of anti-TB active ursolic acid.
The present study explores the variability of biological responses from the perspective of sample purity and introduces the concept of purity-activity relationships (PARs) in natural product research. The abundant plant triterpene ursolic acid (1) was selected as an exemplary natural product due to the overwhelming number yet inconsistent nature of its approximate 120 reported biological activities, which include anti-TB potential. Nine different samples of ursolic acid with purity certifications were obtained, and their purity was independently assessed by means of quantitative 1H NMR (qHNMR). Biological evaluation consisted of determining MICs against two strains of virulent Mycobacterium tuberculosis and IC50 values in Vero cells. Ab initio structure elucidation provided unequivocal structural confirmation and included an extensive 1H NMR spin system analysis, determination of nearly all J couplings and the complete NOE pattern, and led to the revision of earlier reports. As a net result, a sigmoid PAR profile of 1 was obtained, demonstrating the inverse correlation of purity and anti-TB bioactivity. The results imply that synergistic effects of 1 and its varying impurities are the likely cause of previously reported antimycobacterial potential. Generating PARs is a powerful extension of the routinely performed quantitative correlation of structure and activity ([Q]SAR). Advanced by the use of primary analytical methods such as qHNMR, PARs enable the elucidation of cases like 1 when increasing purity voids biological activity. This underlines the potential of PARs as a tool in drug discovery and synergy research and accentuates the need to routinely combine biological testing with purity assessment.
Jaki
Birgit U
BU
Institute for Tuberculosis Research and Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, Illinois 60612-7231, USA.
Franzblau
Scott G
SG
Chadwick
Lucas R
LR
Lankin
David C
DC
Zhang
Fangqiu
F
Wang
Yuehong
Y
Pauli
Guido F
GF
D000818:Animals; D000995:Antitubercular Agents / Q000032:analysis / Q000737:chemistry / Q000494:pharmacology*; D001688:Biological Products / Q000032:analysis / Q000737:chemistry / Q000494:pharmacology*; D002522:Chlorocebus aethiops; D020128:Inhibitory Concentration 50; D015394:Molecular Structure; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D013329:Structure-Activity Relationship; D014315:Triterpenes / Q000032:analysis / Q000737:chemistry / Q000494:pharmacology*; D014709:Vero Cells; D000097245:Ursolic Acid
D000995:Antitubercular Agents; D001688:Biological Products; D014315:Triterpenes; D000097245:Ursolic Acid